Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 ...

logo of US biotech company Novavax. Novavax’s vaccine targets the JN.1 COVID-19 variant, which was the dominant strain circulating in the U.S. earlier this year but now makes up less than 1% of ...

Novavax Inc. closed $10.66 short of its 52-week high ($23.86), which the company reached on June 6th. Supported by ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

U.S. regulators have cleared a third updated Covid-19 vaccine for this fall, shots made by Novavax. Already, Pfizer and Moderna are shipping shots modified to better match more recent strains of ...

U.S. regulators have cleared a third updated COVID-19 vaccine for this fall, shots made by Novavax Inc. Already, Pfizer and Moderna are shipping shots modified to better match more recent strains ...

The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID ... as the end of next week, the company said in an emailed response.

Begin your TipRanks Premium journey today. Novavax (NVAX) Company Description: Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and ...

Shares of Novavax Inc. NVAX slid 2.86% to $12.56 Wednesday, on what proved to be an all-around dismal trading session for the ...

The U.S. Food and Drug Administration today granted emergency use authorization for an updated version of Novavax’s COVID ... Shares of the company were up 2.2% in extended trading after closing ...